Prevalence and characteristics of self-reported kratom use in a representative US general population sample

References

• Cinosi E, Martinotti G, Simonato P, Singh D, Demetrovics Z, Roman-Urrestarazu A, Bersani FS, Vicknasingam B, Piazzon G, Li J-H, et al. Following “the roots” of kratom (Mitragyna speciosa): the evolution of an enhancer from a traditional use to increase work and productivity in Southeast Asia to a recreational psychoactive drug in Western countries. Biomed Res Int. 2015;2015:968786. doi:10.1155/2015/968786.
   PubMed Web of Science ®Google Scholar
• Veltri C, Grundmann O. Current perspectives on the impact of Kratom use. Subst Abuse Rehabil. 2019;10:23–31. doi:10.2147/SAR.S164261.
   PubMed Web of Science ®Google Scholar
• Graziano S, Orsolini L, Rotolo MC, Tittarelli R, Schifano F, Pichini S. Herbal highs: review on psychoactive effects and neuropharmacology. Curr Neuropharmacol. 2017;15(5):750–61. doi:10.2174/1570159X14666161031144427.
   PubMed Web of Science ®Google Scholar
• Kruegel AC, Grundmann O. The medicinal chemistry and neuropharmacology of kratom: A preliminary discussion of a promising medicinal plant and analysis of its potential for abuse. Neuropharmacology. 2018;134(Pt A):108–20. doi:10.1016/j.neuropharm.2017.08.026.
   PubMed Web of Science ®Google Scholar
• White CM. Pharmacologic and clinical assessment of kratom. Am J Health Syst Pharm. 2018;75(5):261–7. doi:10.2146/ajhp161035.
   PubMed Web of Science ®Google Scholar
• Coe MA, Pillitteri JL, Sembower MA, Gerlach KK, Henningfield JE. Kratom as a substitute for opioids: Results from an online survey. Drug Alcohol Depend. 2019;202:24–32. doi:10.1016/j.drugalcdep.2019.05.005.
   PubMed Web of Science ®Google Scholar
• Singh D, Narayanan S, Vicknasingam B. Traditional and non-traditional uses of Mitragynine (Kratom): A survey of the literature. Brain Res Bull. 2016;126(Pt 1):41–6. doi:10.1016/j.brainresbull.2016.05.004.
   PubMedGoogle Scholar
• Smith KE, Lawson T. Prevalence and motivations for kratom use in a sample of substance users enrolled in a residential treatment program. Drug Alcohol Depend. 2017;180:340–8. doi:10.1016/j.drugalcdep.2017.08.034.
   PubMed Web of Science ®Google Scholar
• Singh D, Müller CP, Vicknasingam BK. Kratom (Mitragyna speciosa) dependence, withdrawal symptoms and craving in regular users. Drug Alcohol Depend. 2014;139:132–7. doi:10.1016/j.drugalcdep.2014.03.017.
   PubMed Web of Science ®Google Scholar
• Singh D, Narayanan S, Vicknasingam B, Corazza O, Santacroce R, Roman u. A. Changing trends in the use of kratom (Mitragyna speciosa) in Southeast Asia. Hum Psychopharmacol. 2017;32:e2582. 10.1002/hup.2582.
   PubMed Web of Science ®Google Scholar
• Vicknasingam B, Narayanan S, Beng GT, Mansor SM. The informal use of ketum (Mitragyna speciosa) for opioid withdrawal in the northern states of peninsular Malaysia and implications for drug substitution therapy. Int J Drug Policy. 2010;21(4):283–8. doi:10.1016/j.drugpo.2009.12.003.
   PubMed Web of Science ®Google Scholar
• Diep J, Chin DT, Gupta S, Syed F, Xiong M, Cheng J. Kratom, an emerging drug of abuse: a case report of overdose and management of withdrawal. A A Pract. 2018;10(8):192–4. doi:10.1213/XAA.0000000000000658.
   PubMed Web of Science ®Google Scholar
• Cumpston KL, Carter M, Wills BK. Clinical outcomes after kratom exposures: a poison center case series. Am J Emerg Med. 2018;36(1):166–8. doi:10.1016/j.ajem.2017.07.051.
   PubMed Web of Science ®Google Scholar
• Forrester MB. Kratom exposures reported to Texas poison centers. J Addict Dis. 2013;32(4):396–400. doi:10.1080/10550887.2013.854153.
   PubMed Web of Science ®Google Scholar
• Neerman MF, Frost RE, Deking J. A drug fatality involving kratom. J Forensic Sci. 2013;58:S278–S9. doi:10.1111/1556-4029.12009.
   PubMed Web of Science ®Google Scholar
• Post S, Spiller HA, Chounthirath T, Smith GA. Kratom exposures reported to United States poison control centers: 2011-2017. Clin Toxicol (Phila)). 2019;57(10):847–54. doi:10.1080/15563650.2019.1569236.
   PubMed Web of Science ®Google Scholar
• Ohio Academy of Family Physicians. Pharmacy board seeks comments on classification of kratom as Schedule I controlled substance. 2018 [accessed 2020 Mar 17]. https://www.ohioafp.org/wfmu-article/pharmacy-board-seeks-comments-on-classification-of-kratom-as-schedule-i-controlled-substance/.
   Google Scholar
• The Morning Call. Kratom has been linked to numerous deaths, but it’s legal in Pennsylvania and likely will remain so. 2019 [accessed 2020 Mar 17]. https://www.mcall.com/news/pennsylvania/mc-nws-pa-kratom-controversy-pennsylvania-legal-20190901-diorp4vsurf6nckzruswhknjtq-story.html.
   Google Scholar
• WBOC. Is Kratom legal? This is what you need to know. 2019 [accessed 2020 Mar 17]. http://www.wboc.com/story/41496659/is-kratom-legal-this-is-what-you-need-to-know.
   Google Scholar
• Anwar M, Law R, Schier J. Notes from the Field: Kratom (Mitragyna speciosa) Exposures Reported to Poison Centers - United States, 2010-2015. MMWR Morb Mortal Wkly Rep. 2016;65(29):748–9. doi:10.15585/mmwr.mm6529a4.
   PubMed Web of Science ®Google Scholar
• Henningfield JE, Fant RV, Wang DW. The abuse potential of kratom according the 8 factors of the controlled substances act: implications for regulation and research. Psychopharmacology (Berl). 2018;235(2):573–89. doi:10.1007/s00213-017-4813-4.
   PubMed Web of Science ®Google Scholar
• United States Drug Enforcement Administration. DEA announces intent to schedule kratom. Drug Enforcement Administration. 2016 August 30 [accessed 2019 Aug 5]. https://www.dea.gov/press-releases/2016/08/30/dea-announces-intent-schedule-kratom.
   Google Scholar
• Daley J. FDA declares kratom an opioid. We’re here to explain what it does. The Scientist. 2018 February 7 [accessed 2019 August 8]. https://www.the-scientist.com/news-analysis/fda-declares-kratom-an-opioid-were-here-to-explain-what-it-does-30306.
   Google Scholar
• Swogger MT, Hart E, Erowid F, Erowid E, Trabold N, Yee K, Parkhurst KA, Priddy BM, Walsh Z. Experiences of kratom users: a qualitative analysis. J Psychoactive Drugs. 2015;47(5):360–7. doi:10.1080/02791072.2015.1096434.
   PubMed Web of Science ®Google Scholar
• Bhutada NS, Rollins BL. Disease-specific direct-to-consumer advertising of pharmaceuticals: An examination of endorser type and gender effects on consumers' attitudes and behaviors. Res Social Adm Pharm. 2015;11(6):891–900. doi:10.1016/j.sapharm.2015.02.003.
   PubMed Web of Science ®Google Scholar
• Patterson JA, Holdford DA. Pharmacy patronage and service utilization: Associations with patient sociodemographic and health characteristics. J Am Pharm Assoc (2003)). 2019;59(5):660–9. doi:10.1016/j.japh.2019.04.022.
   PubMed Web of Science ®Google Scholar
• Prather AA, Gottlieb LM, Giuse NB, Koonce TY, Kusnoor SV, Stead WW, Adler NE. National Academy of Medicine Social and Behavioral Measures: associations with self-reported health. Am J Prev Med. 2017;53(4):449–56. doi:10.1016/j.amepre.2017.02.010.
   PubMed Web of Science ®Google Scholar
• Soucy JN, Hadjistavropoulos HD. Treatment acceptability and preferences for managing severe health anxiety: Perceptions of internet-delivered cognitive behaviour therapy among primary care patients. J Behav Ther Exp Psychiatry. 2017;57:14–24. doi:10.1016/j.jbtep.2017.02.002.
   PubMed Web of Science ®Google Scholar
• Varisco TJ, Fleming ML, Bapat SS, Wanat MA, Thornton D. Health care practitioner counseling encourages disposal of unused opioid medications. J Am Pharm Assoc (2003)). 2019;59(6):809–15.e5. doi:10.1016/j.japh.2019.07.010.
   PubMed Web of Science ®Google Scholar
• Kapil V, Green JL, Le Lait MC, Wood DM, Dargan PI. Misuse of the γ-aminobutyric acid analogues baclofen, gabapentin and pregabalin in the UK. Br J Clin Pharmacol. 2014;78(1):190–1. doi:10.1111/bcp.12277.
   PubMed Web of Science ®Google Scholar
• Nicewonder JA, Buros AF, Veltri CA, Grundmann O. Distinct kratom user populations across the United States: A regional analysis based on an online survey. Hum Psychopharmacol. 2019;34:e2709. 10.1002/hup.2709.
   PubMed Web of Science ®Google Scholar
• Grundmann O. Patterns of Kratom use and health impact in the US-results from an online survey. Drug Alcohol Depend. 2017;176:63–70. doi:10.1016/j.drugalcdep.2017.03.007.
   PubMed Web of Science ®Google Scholar
• Hedegaard H, Miniño AM, Warner M. Drug overdose deaths in the United States, 1999–2017. Hyattsville, MD: National Center for Health Statistics; 2018. NCHS Data Brief, no 329.
   Google Scholar
• Boyer EW, Babu KM, Adkins JE, Mccurdy CR, Halpern JH. Self-treatment of opioid withdrawal using kratom (Mitragynia speciosa korth). Addiction. 2008;103(6):1048–50. doi:10.1111/j.1360-0443.2008.02209.x.
   PubMed Web of Science ®Google Scholar
• Eldridge WB, Foster C, Wyble L. Neonatal abstinence syndrome due to maternal kratom use. Pediatrics. 2018;142(6):e20181839. doi:10.1542/peds.2018-1839.
   PubMed Web of Science ®Google Scholar